ConCallIQ
Go Pro
APOLLOHOSP Healthcare 15 Jan 2024

Apollohosp Ltd — Q3 FY24

Apollo Hospitals reported a strong Q3 FY24 with consolidated revenue of INR 4,851 crore (+14% YoY) and EBITDA of INR 614 crore (+21% YoY).

bullish high
Revenue ₹4,851 Cr +14%
EBITDA ₹614 Cr +21%
PAT ₹254 Cr +56%
EBITDA Margin 13%
Duration
Read Time 1 min read

✓ Verified against BSE filing

2-Minute Summary

✦ AI-Generated from Full Transcript

Apollo Hospitals reported a strong Q3 FY24 with consolidated revenue of INR 4,851 crore (+14% YoY) and EBITDA of INR 614 crore (+21% YoY). PAT surged 56% YoY to INR 245 crore, driven by robust healthcare services growth (12% YoY) and a significant milestone: Apollo HealthCo achieved break-even a quarter early. Hospital occupancy stood at 66%, with ARPOB up 10% to INR 56,368. Management guided for 200 bps margin improvement in healthcare services over the next few quarters, supported by volume growth and cost rationalization. The 24/7 digital platform is expected to break even in 6-8 quarters, with new revenue streams like insurance distribution and digital therapeutics. A 2,000-bed expansion plan over four years is underway. Key risk: new bed additions may temporarily pressure margins if ramp-up is slower than expected.

Key Numbers

Hospital Occupancy 66%
Flat YoY

Occupancy remained at 66% despite seasonal headwinds and reduction in dialysis volumes.

ARPOB INR 56,368
+10% YoY

Average revenue per occupied bed increased 10% YoY, driven by pricing and case mix improvements.

24/7 GMV INR 658 crore
+21% QoQ

Gross merchandise value of the digital platform grew 21% sequentially, with 2 million new users added.

Insurance Revenue Share 43%
+16% YoY

Insurance revenues grew 16% YoY, now contributing 43% of total hospital IP revenue.

What Changed vs Last Quarter

Comparing Q3 FY24 vs Q2 FY24
2 new guidance2 dropped4 new risk3 risk resolved
NEW
Healthcare services revenue growth of 15% for FY24

Management expects 15% revenue growth for the full year, with Q3 impacted by seasonality but confident of achieving at least 14%.

NEW
200 bps margin improvement in healthcare services over next few quarters

Internal target to increase EBITDA margins by 200 basis points through volume growth, clinical program expansion, and cost rationalization.

UPDATED
Apollo 24/7 break-even in 6-8 quarters

Digital platform expected to achieve profitability within six to eight quarters, driven by new verticals like insurance distribution and digital therapeutics.

UPDATED
2,000 beds over four years at INR 3,000 crore capex

Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.

DROPPED
Hospital EBITDA margin expansion of 200 bps

Management expects hospital EBITDA margins to improve by 200 basis points over the next two years, driven by operating leverage and occupancy improvement.

DROPPED
Pharmacy omni-channel revenue of INR 10,000 crore and 6%+ EBITDA margin

Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher.

NEW RISK
Margin pressure from new bed additions

New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.

NEW RISK
Seasonality and one-off events impacting growth

Q3 saw lower elective surgeries due to holidays and Chennai cyclone, affecting revenue mix and margins. Similar events could recur.

NEW RISK
Slowdown in 24/7 daily active users

Despite adding 2 million new users, daily active users declined sequentially, raising concerns about user engagement and monetization.

NEW RISK
Regulatory risk from kidney racket allegations

Allegations of involvement in a kidney racket could impact reputation, though management states no negative findings have been made.

RISK GONE
Delayed monsoon impacted medical admissions in South India

Inpatient volume growth was muted in core southern markets due to a delayed monsoon, reducing seasonal medical admissions.

RISK GONE
New hospital ramp-up may pressure near-term margins

Analyst raised concern that new bed additions (Pune, Kolkata, Hyderabad) could drag margins until they reach breakeven in 12-18 months.

RISK GONE
Competitive intensity in metro markets

Analyst questioned whether expansion in metros (where supply is strong) is prudent versus non-metros where Apollo has an early-mover advantage.

🤫 Topics management stopped discussing

Apollo 24|7 operational breakeven in Q4 FY24

Mentioned in Q1 FY24, Q2 FY24

The digital health platform is expected to achieve operational breakeven by the fourth quarter of FY24.

Combined pharmacy revenue target of INR 10,000 crore with 6% EBITDA margin

Mentioned in Q1 FY24, Q2 FY24

Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher.

Management Guidance

G

Healthcare services revenue growth of 15% for FY24

Management expects 15% revenue growth for the full year, with Q3 impacted by seasonality but confident of achieving at least 14%.

Management guidance revenue
G

200 bps margin improvement in healthcare services over next few quarters

Internal target to increase EBITDA margins by 200 basis points through volume growth, clinical program expansion, and cost rationalization.

Management guidance margins
G

Apollo 24/7 break-even in 6-8 quarters

Digital platform expected to achieve profitability within six to eight quarters, driven by new verticals like insurance distribution and digital therapeutics.

Management guidance growth
G

2,000 beds over four years at INR 3,000 crore capex

Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.

Management guidance capex

Key Risks

R

Margin pressure from new bed additions

New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.

medium · analyst_question
R

Seasonality and one-off events impacting growth

Q3 saw lower elective surgeries due to holidays and Chennai cyclone, affecting revenue mix and margins. Similar events could recur.

low · management_commentary
R

Slowdown in 24/7 daily active users

Despite adding 2 million new users, daily active users declined sequentially, raising concerns about user engagement and monetization.

medium · analyst_question
R

Regulatory risk from kidney racket allegations

Allegations of involvement in a kidney racket could impact reputation, though management states no negative findings have been made.

low · analyst_question

Notable Quotes

We have delivered ahead of time on a bit of break-even for Apollo HealthCo. I'm sure we will continue to deliver on our strategic intent.
Suneeta Reddy · Managing Director, Apollo Hospitals
Internally, we would like to believe that there is an opportunity to increase the margins by at least 200 basis points over the next few quarters.
Krishnan Akhileswaran · Group CFO, Apollo Hospitals
Our entire growth is being led by volume. We are bullish that we'll be able to sustain at 20% kind of growth levels.
Sriram Iyer · CEO of Apollo Health and Lifestyle Limited

Frequently Asked Questions

What was Apollohosp's revenue in Q3 FY24?

Apollohosp reported revenue of ₹4,851 Cr in Q3 FY24, representing a +14% change compared to the same quarter last year.

What guidance did Apollohosp management give for FY25?

Healthcare services revenue growth of 15% for FY24: Management expects 15% revenue growth for the full year, with Q3 impacted by seasonality but confident of achieving at least 14%. 200 bps margin improvement in healthcare services over next few quarters: Internal target to increase EBITDA margins by 200 basis points through volume growth, clinical program expansion, and cost rationalization. Apollo 24/7 break-even in 6-8 quarters: Digital platform expected to achieve profitability within six to eight quarters, driven by new verticals like insurance distribution and digital therapeutics. 2,000 beds over four years at INR 3,000 crore capex: Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.

What are the key risks for Apollohosp in FY25?

Key risks include Margin pressure from new bed additions — New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.; Seasonality and one-off events impacting growth — Q3 saw lower elective surgeries due to holidays and Chennai cyclone, affecting revenue mix and margins. Similar events could recur.; Slowdown in 24/7 daily active users — Despite adding 2 million new users, daily active users declined sequentially, raising concerns about user engagement and monetization.; Regulatory risk from kidney racket allegations — Allegations of involvement in a kidney racket could impact reputation, though management states no negative findings have been made..

Did Apollohosp meet its previous quarter's guidance?

Of 1 tracked promise, management 0 met, 0 close, 1 missed.

Where can I read the full Apollohosp Q3 FY24 concall transcript?

The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.